A Dose and Schedule Finding Trial with AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults with Lymphoma

- Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14, Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab - Has adequate bone marrow function; platelet count > 100 x 10^9/L on the day of initiation of the on study chemotherapy of the next treatment cycle and absolute neutrophil count, ANC > or = 1 x 10^9/L, and hemoglobin > or = 9.5 g/dL - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Has adequate liver function - must be able to receive the same chemotherapy regimen during the first treatment cycle as was received during the prior qualifying cycle - must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia (platelet count < 50 x 10^9/L) as a result of the chemotherapy administered in the cycle immediately preceding study entry - has serum creatinine concentration < or = 2 mg/dl

- More that 1 prior relapse chemotherapy regimen - Sepsis, disseminated coagulation or any other condition that may exacerbate thrombocytopenia - Significant bleeding (CTC grade 3 or 4) - History of thromboembolic disease - Subjects who are identified by clinical history and/or serological testing to have either acute or chronic hepatitis B or C infection or to be HIV positive - Use of any nitrosourea or mitomycin-C - Has received any thrombocytopenic growth factor - Has received a marrow or peripheral blood stem cell infusion - Known hypersensitivity to any recombinant E. coli-derived product